FTC Chair Khan slams PBMs for higher drug prices in an interim report on the industry

The FTC's report blames top PBMs for high drug prices due to consolidation and market dominance. The "Big Three" PBMs control 80% of US prescriptions, with revenues rising to over $1 trillion. Smaller PBMs like Navitus seek reform for a more transparent healthcare system.